Clinical Trial Update: Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial investigating redox regulation in relapsed or refractory CD20+ non-Hodgkin's lymphoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Snippet

Sponsor: Northwestern University | Conditions: Non-Hodgkin's Lymphoma (NHL) | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2019-08-14